<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00077753</url>
  </required_header>
  <id_info>
    <org_study_id>XRP4563C_3501</org_study_id>
    <nct_id>NCT00077753</nct_id>
  </id_info>
  <brief_title>EXCLAIM:Extended Prophylaxis for Venous ThromboEmbolism (VTE) in Acutely Ill Medical Patients With Prolonged Immobilization</brief_title>
  <official_title>A Double-Blind, Placebo-Controlled, Parallel, Multicenter Study on Extended VTE Prophylaxis in Acutely Ill Medical Patients With Prolonged Immobilization</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      Primary objective:&#xD;
&#xD;
        -  To demonstrate the superiority of extended VTE prophylaxis with enoxaparin 40mg sc qd&#xD;
           for 28 ± 4 days, compared to placebo, both following 10 ± 4 days of initial treatment&#xD;
           with enoxaparin 40mg sc qd&#xD;
&#xD;
      Secondary objectives:&#xD;
&#xD;
        -  To assess the reduction in mortality rate at the end of the double-blind treatment&#xD;
           period, at 3 (90 ± 10 days) and at 6 (180 ± 10 days) months from the time of entry to&#xD;
           the study, in patients on extended prophylaxis&#xD;
&#xD;
        -  To assess the incidence of VTE at 3 months (90 ± 10 days) from the time of randomization&#xD;
           to the study&#xD;
&#xD;
        -  To evaluate the safety of extended enoxaparin VTE prophylaxis in acutely ill medical&#xD;
           patients with prolonged immobilization. Safety evaluation includes:&#xD;
&#xD;
             -  Major and minor hemorrhage&#xD;
&#xD;
             -  Heparin induced thrombocytopenia&#xD;
&#xD;
             -  Serious adverse events&#xD;
&#xD;
        -  To assess differences in levels of health-care utilization and cost between patients&#xD;
           receiving extended VTE prophylaxis versus those receiving placebo.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2002</start_date>
  <completion_date type="Actual">February 2007</completion_date>
  <primary_completion_date type="Actual">October 2006</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>During double blind treatment : Cumulative occurrence of VTE assessed by ultrasound for all patients at 28±4 days after randomization (or earlier if symptomatic VTE) and/or V/Q lung scan for symptomatic patients ; Major hemorrhagic complications.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurrence of VTE between Day 1 and Day 90±10, Mortality at the end of Double-Blind Treatment, at 3 and 6 months</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minor plus major hemorrhagic complications during Double-Blind Treatment.</measure>
  </secondary_outcome>
  <enrollment>4726</enrollment>
  <condition>Venous Thromboembolism</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>enoxaparin sodium</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Recent immobilization ≤ 3 days&#xD;
&#xD;
          -  Level 1 mobility patients who are ≥ 40 years of age with acute medical illness or&#xD;
             acute exacerbation of chronic medical illness&#xD;
&#xD;
          -  Level 2 mobility patients who&#xD;
&#xD;
               -  are &gt;75 yrs of age&#xD;
&#xD;
               -  are ≥ 40 years of age and have a history of VTE (deep venous thrombosis or&#xD;
                  pulmonary embolism)&#xD;
&#xD;
               -  are ≥ 40 years of age and have a baseline diagnosis of cancer (active cancer or&#xD;
                  history of cancer)&#xD;
&#xD;
        Anticipated decreased level of mobility of 5 ± 2 days with a level of activity 1 and 2 at&#xD;
        the time of study entry and likely to continue at a lower than pre-morbid activity level&#xD;
        after the initial 5 ± 2 day period. PATIENTS DO NOT HAVE TO BE HOSPITALIZED IN ORDER TO BE&#xD;
        INCLUDED IN THE STUDY.(Definition of decreased level of mobility: _Level 1:bed rest or&#xD;
        sedentary patients _Level 2:level 1 with bathroom privileges)&#xD;
&#xD;
          -  Presence of at least one of the following medical conditions:&#xD;
&#xD;
               -  Heart Failure, NYHA class III and IV&#xD;
&#xD;
                    -  Class III : Patients with cardiac disease resulting in marked limitation of&#xD;
                       physical activity. They are comfortable at rest. Less than ordinary physical&#xD;
                       activity causes fatigue, palpitationdyspnea, or anginal pain.&#xD;
&#xD;
                    -  Class IV : Patients with cardiac disease resulting in inability to carry on&#xD;
                       any physical activity without discomfort. Symptoms of cardiac insufficiency&#xD;
                       or of the anginal syndrome may be present even at rest. If any physical&#xD;
                       activity is undertaken, discomfort is increased.&#xD;
&#xD;
               -  Acute respiratory insufficiency&#xD;
&#xD;
               -  Other acute medical conditions such as:&#xD;
&#xD;
                    -  Acute ischemic stroke, any territory, with an appropriate neuroradiologic&#xD;
                       (head CT scan or brain MRI scan) providing results consistent with non&#xD;
                       hemorrhagic stroke&#xD;
&#xD;
                    -  acute infection without septic shock&#xD;
&#xD;
                    -  acute rheumatic disorders&#xD;
&#xD;
                    -  active episode of inflammatory bowel disease&#xD;
&#xD;
                    -  active cancer defined as history of histologically or cytologically&#xD;
                       confirmed cancer in patients who are not candidates for debulking or&#xD;
                       curative intent surgery at study entry&#xD;
&#xD;
                    -  Any other acute medical illness or exacerbation of chronic medical illness&#xD;
                       resulting in clinically significant reduction in mobility as compared to&#xD;
                       premorbid level.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Women who are breastfeeding, pregnant or of childbearing age and not using medically&#xD;
             acceptable effective contraception&#xD;
&#xD;
          -  Patients with any evidence of an active bleeding disorder&#xD;
&#xD;
          -  Contraindication to anticoagulation&#xD;
&#xD;
          -  Major surgery within the previous 3 months&#xD;
&#xD;
          -  Patients who have had spinal or epidural analgesia or lumbar puncture within the&#xD;
             preceding 24 hours&#xD;
&#xD;
          -  Known hypersensitivity to heparin, or LMWH, or pork derived products&#xD;
&#xD;
          -  A documented previous episode of heparin-induced or LMWH induced thrombocytopenia&#xD;
             and/or thrombosis (HIT, HAT, or HITTS)&#xD;
&#xD;
          -  Patients who have taken part in another clinical trial within the previous thirty days&#xD;
&#xD;
          -  Patients with a persistent renal failure. The patient's creatinine level must be less&#xD;
             than the creatinine level per gender/age/weight. This will replace the calculated&#xD;
             creatinine clearance&#xD;
&#xD;
          -  Known or suspected severe anemia of unexplained cause considered clinically relevant&#xD;
             by investigator&#xD;
&#xD;
          -  Patients with prosthetic heart valves&#xD;
&#xD;
          -  Patients with known cerebral metastases&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luc Sagnard</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Bridgewater</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>North Ryde</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Laval</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Bogota</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Mumbai</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Natanya</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Mexico</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Johannesburg</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Megrine</city>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Guildford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Colombia</country>
    <country>France</country>
    <country>Germany</country>
    <country>India</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Mexico</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Tunisia</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2011</verification_date>
  <study_first_submitted>February 12, 2004</study_first_submitted>
  <study_first_submitted_qc>February 13, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 16, 2004</study_first_posted>
  <last_update_submitted>January 10, 2011</last_update_submitted>
  <last_update_submitted_qc>January 10, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 11, 2011</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Enoxaparin</mesh_term>
    <mesh_term>Enoxaparin sodium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

